Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd has announced the record date for remote e-voting for its 22nd Annual General Meeting (AGM). The AGM is scheduled for Saturday, August 29, 2026. The cut-off date for shareholders to be eligible for remote e-voting is Saturday, August 22, 2026. The remote e-voting period will commence on Tuesday, August 25, 2026, at 9:00 AM and conclude on Friday, August 28, 2026, at 5:00 PM. Mr. Avinash Gandhewar, Practicing Company Secretary, has been appointed as the scrutinizer for the e-voting process.

Goldline Pharmaceutical Ltd has announced its 22nd Annual General Meeting (AGM) will be held on Saturday, August 29, 2026, at 4:00 PM at Hotel Airport Centre Point, Nagpur. The meeting agenda includes the adoption of audited financial statements for the year ended March 31, 2026, declaration of dividend on preference shares, re-appointment of director Mr. Prashant Shrikrishna Karkare, and approval of material related party transactions with Activista Healthcare Private Limited and Nucleage Pharma Solutions Private Limited. The notice of the AGM, including the detailed agenda and resolutions, has been filed with the exchange.

Prashant Shrikrishna Karkare, an Executive Director at Goldline Pharmaceutical Ltd, has acquired 27,000 equity shares, representing 0.28% of the company's total issued and paid-up share capital. The acquisition was made through open market purchases on July 28, 2026. This disclosure is made in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The total issued share capital remains 9,600,000 equity shares post-acquisition.

Goldline Pharmaceutical Ltd has appointed M/s. Avinash Prakash Gandhewar, Practicing Company Secretaries, as its Secretarial Auditor for the financial year 2025-26. The appointment was approved by the Board of Directors in a meeting held on July 14, 2026. The firm, M/s Avinash Gandhewar & Associates, has expertise in company law, securities laws, and other corporate compliance matters. This appointment is in compliance with SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Swapan Khandelwal, Promoter and Whole Time Director of Goldline Pharmaceutical Limited, has acquired 60,000 equity shares through an open market purchase. The acquisition took place on June 22, 2026. Prior to this transaction, Khandelwal held 2,749,988 shares, representing 28.65% of the total paid-up capital. After the acquisition, his total holding increased to 2,809,988 shares, which constitutes 29.27% of the company's total paid-up capital. This disclosure is made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Swapan Khandelwal, Promoter and Whole Time Director of Goldline Pharmaceutical Ltd, has acquired 60,000 equity shares, representing 0.62% of the total issued and paid-up share capital. The acquisition was made through open market purchases on June 22, 2026. Following this transaction, Khandelwal's total holding in the company increased to 29.27%. This disclosure is made pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Mr. Swapan Khandelwal, Promoter and Whole Time Director of Goldline Pharmaceutical Ltd, has acquired 60,000 equity shares, representing 0.62% of the total issued and paid-up share capital. The acquisition was made through open market purchases on June 22, 2026. Following this transaction, Mr. Khandelwal's total holding in the company has increased to 29.27%. This disclosure is made pursuant to Regulation 29(2) of SEBI (SAST) Regulations, 2011.

Goldline Pharmaceutical Ltd announced the outcome of its Board Meeting held on June 9, 2026. The board approved the standalone audited financial results for the half-year and full year ended March 31, 2026. Additionally, M/s. Kunal Dutt & Associates were appointed as the Internal Auditor for the company starting from the financial year 2026-27. The financial results will be disseminated on the company's website. The meeting commenced at 4:30 PM and concluded at 5:06 PM.

Goldline Pharmaceutical Ltd has announced the appointment of M/s. Kunal Dutt & Associates as its Internal Auditors, effective from the financial year 2026-27. The decision was approved by the Board of Directors following a recommendation from the Audit Committee. M/s. Kunal Dutt & Associates is a firm of Practicing Company Secretaries known for its expertise in corporate law, compliance, and governance. They are not related to any Director or Key Managerial Personnel of the company. This appointment is a routine corporate governance measure.

Goldline Pharmaceutical Ltd announced the outcome of its Board Meeting held on June 9, 2026. The board approved the standalone audited financial results for the half-year and full year ended March 31, 2026. Additionally, M/s. Kunal Dutt & Associates were appointed as the Internal Auditor for the company starting from the financial year 2026-27. The financial results will be disseminated on the company's website. The meeting commenced at 4:30 PM and concluded at 5:06 PM.